Study Group: Seroquel Prescribers forSchizophrenia (US)
Council Members in this Study Group: 109
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- David Rosenberg, MD
Chief of Psychiatry and Psychology
CHILDREN'S HOSPITAL OF MICHIGAN
David Rosenberg, MD, is a tenured Professor and Miriam L Hamburger Endowed Chair of Psychiatry at Wayne State University and the Children's Hospital of Michigan. He is a board certified general and adult psychiatrist and pediatric psychiatrist. Dr. Rosenberg has authored first ever textbook on pediatric...
Amit Vijapura, MDOwner
AMIT VIJAPURA MDAmit Vijapura, MD, is a Private Practitioner in Psychiatry based in Florida. He has over 15 years of experience in the field and has expertise in depression, bipolar disorder, anxiety disorder, attention deficient disorder, and schizophrenia. Dr. Vijapura is board certified in Psychiatry and is also...
- Robert Schulte
Psychiatrist
North Scottsdale Psychiatric SpecialistsRobert Schulte, MD, is a Private Practitioner and a Psychiatrist at North Scottsdale Psychiatric Specialists in Arizona. He is board certified in Adult Psychiatry and Child and Adolescent Psychiatry with extensive experience with children and adult's re-psychotherapy and psychopharmacology and thetreatment...
- Rami Kaminski, MD
Founder and Director
Institute for Integrative PsychiatryRami Kaminski, MD, is Director and Founder of the Institute for Integrative Psychiatry in New York, a not-for-profit organization aimed at evaluating current psychiatric services and how they integrate with medicine, such as the mutual effects between medical and psychiatric conditions. Prior to that,...
- Lawrence Ginsberg, MD
President
RED OAK PSYCHIATRY ASSOCIATES, P. A.Lawrence Ginsberg, MD, is President and CEO of Red Oak Psychiatry Associates, PA, a multidisciplinary mental health group in Houston, Texas. Dr. Ginsberg's research interests include psychopharmacology, addiction medicine, and forensic psychiatry. His areas of clinical expertise are attention deficit...
GLG NewsSM Analyses by this Study Group's Leading Experts (?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Antidepressants Vary More in Side Effects, Not Efficacy
August 30, 2009
2nd Generation Antidepressants Prove Effective | health.usnews.com
[SIDE EFFECTS] The main differences among the newer antidepressants are side effects and drug interactions. See the Commentary for a drug-by-drug list of these key differences. [PCP's] This review comes from a group of primary care docs, which is important because most depression is treated by PCPs....
-
State Medicaid Cuts May Limit Market for New Antipsychotic Lurasidone
August 30, 2009
LURASIDONE DEMONSTRATED EFFICACY IN TREATING PATIENTS WITH SCHIZOPHRENIA IN PIVOTAL PHASE 3 STUDY | www.pipelinereview.com
Lurasidone is an atypical antipsychotic owned by Dainippon Sumitomo Pharma. Phase 3 PEARL 1 Study: 6-week, multi-site, double-blind placebo-controlled trial in 500 pts with DSM4 schizophrenia with PANSS score greater than 80. RESULTS: 80mg dose was superior to placebo; 40mg & 120mg was not....
-
June 15, 2009
Bayer completes Phase II Study on BAY 94-9172 in Alzheimer’s Disease Imaging | www.pipelinereview.com
There is a larger potential benefit from the use of amyloid imaging. Of course refining diagnosis is important. But research involving drugs in development, particularly vaccines, relies on the measurement of amyloid in the brain. To some degree this can be done by looking at spinal...
-
March 23, 2009
New Alzheimer's disease drugs available with five years | www.nursingtimes.net
The bottom line is that there are many, many drugs in development for the treatment of Alzheimer's (more than the speaker quoted in the article estimates) and, therefore, it is likely that some will be on the market in 5-10 years. However, they are not necessarily going to be cures or totally...
-
November 24, 2008
2nd Generation Antidepressants Prove Effective | health.usnews.com
This article tells you only that the drugs are equally effective, but not what that really means in real life.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Other Freestanding Healthcare Facility
- Private/For-Profit Healthcare Research Entity
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Owner
- Physician - Director
- Director
- Physician - Division Head
- Medical Director
- President
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Physicians who Treat Schizophrenia (US) | 371 |
| Psychiatrists (US) | 1155 |
| Psychiatrists | 1554 |
| Physicians who Treat ADHD (US) | 459 |
| Physicians who Treat Depression (US) | 450 |
| Effexor XR Prescribers (US) | 148 |
| SSRI Prescribers (US) | 278 |